Adiponectin enhancer, oral composition for enhancing adiponectin, and use of plasmalogen

Abstract

To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an adiponectin enhancer, an oral composition for enhancing adiponectin, and use of plasmalogens. [Background technology]

[0002] Adiponectin is a protein secreted from adipocytes. Adiponectin is known to have various functions, such as activating PPARα, which promotes fatty acid burning in skeletal muscles, and AMP kinase, which promotes fatty acid burning and glucose uptake. Since adiponectin improves insulin resistance in skeletal muscles and the liver, drugs that increase the expression of adiponectin are being researched.

[0003] Patent Document 1 discloses an adiponectin enhancer containing hop extract as an active ingredient. Non-Patent Documents 1, 2, 3, and 4 disclose that thiazolidinediones (TZDs), metformin, omega-3 fatty acids, and resveratrol, respectively, increase serum adiponectin. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2006-306800 A [Non-patent literature]

[0005] [Non-Patent Document 1] Norikazu Maeda, 14 others, "PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein", DIABETES, 2001, 50(9), 2094-2099 [Non-Patent Document 2] N Adamia, 4 others, "Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes", Georgian Med News., 2007, 145, 52-55 [Non-Patent Document 3] Mehdi Bahreni, et al., “The Effect of Omega-3 on Circulating Adiponectin in Adults With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”, Can J Diabetes, 2018, 42, 553-559 [Non-Patent Document 4] Cintia dos Santos Costa, and 7 others, "Resveratrol Upregulated SIRT1, FOXO1, and Adiponectin and Downregulated PPARγ1-3 mRNA Expression in Human Visceral Adipocytes", OBES SURG, 2011, 21, 356-361 Summary of the Invention [Problem to be solved by the invention]

[0006] As described above, various substances are being investigated as drugs that enhance adiponectin. In order to ensure the diversity of such drugs that can be used clinically, drug candidates that enhance adiponectin are needed.

[0007] The present invention has been made in view of the above circumstances, and aims to provide an adiponectin enhancer having an adiponectin enhancing effect and an oral composition for enhancing adiponectin. The present invention also aims to provide use of plasmalogen for producing the adiponectin enhancer or the oral composition for enhancing adiponectin. [Means for solving the problem]

[0008] The adiponectin enhancer according to the first aspect of the present invention comprises: Contains plasmalogen as an active ingredient.

[0009] The oral composition for enhancing adiponectin according to the second aspect of the present invention comprises: Contains plasmalogen as an active ingredient.

[0010] The plasmalogen is It is a plasmalogen extracted from animal tissue. This may also be the case.

[0011] The animal tissue comprises: The tissue is an animal selected from the group consisting of shellfish, sea squirts and birds. This may also be the case.

[0012] The animal tissue comprises: Scallop tissue, This may also be the case.

[0013] The use according to the third aspect of the present invention comprises: The present invention relates to use of a plasmalogen for producing an adiponectin enhancer or an oral composition for enhancing adiponectin. Effect of the Invention

[0014] According to the present invention, there are provided an adiponectin enhancer having an adiponectin enhancing effect and an oral composition for enhancing adiponectin. Furthermore, according to the present invention, there is provided use of plasmalogen for producing the adiponectin enhancer or the oral composition for enhancing adiponectin. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows the results of Western blotting for rats in an example. [Diagram 2] 2A is a micrograph of small intestinal tissue of a rat in an example, obtained by immunohistochemical staining, and B is a diagram showing the relative number of adiponectin-expressing cells quantified from the micrograph shown in FIG. [Diagram 3] FIG. 2 is a diagram showing the relative amount of adiponectin in serum of rats in an example. [Figure 4] 4A is a micrograph of small intestinal tissues of a mouse in an example, obtained by immunohistochemical staining, and B is a diagram showing the relative number of adiponectin-expressing cells quantified from the micrograph shown in FIG. [Diagram 5] FIG. 2 is a diagram showing the relative expression level of RNA (AdipoQ) encoding adiponectin in cultured mouse intestinal epithelial tissue according to an example. [Figure 6] FIG. 1 shows the relative amount of adiponectin in a culture supernatant according to an example. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The embodiments of the present invention will be described with reference to the drawings. Note that the present invention is not limited to the following embodiments and drawings. Note that in the following embodiments, the expressions "have", "include" and "contain" also include the meaning of "consisting of" or "consisting of".

[0017] The adiponectin enhancer according to the present embodiment contains plasmalogen as an active ingredient. Plasmalogen belongs to a subclass of glycerophospholipids that is characterized by having a vinyl ether bond at the sn-1 position of the glycerol backbone and an ester bond at the sn-2 position. Plasmalogen is present at high concentrations in the cell membranes of many mammalian tissues.

[0018] The plasmalogen contained in the adiponectin enhancer is not particularly limited as long as it is generally classified as a plasmalogen. Examples of plasmalogens include Pls, PlsCho, inositol-type plasmalogens, and serine-type plasmalogens. Pls has a structure in which -CH2CH2NH2 is bound to the oxygen atom bound to phosphorus at the sn-3 position of the glycerol backbone. PlsCho has a structure in which -CH2CH2N(CH3)3 is bound to the oxygen atom bound to phosphorus at the sn-3 position of the glycerol backbone.

[0019] Preferably, the plasmalogen is extracted from an animal tissue. The animal tissue is not particularly limited as long as it contains plasmalogen. For example, the animal tissue may be tissue of an animal selected from the group consisting of shellfish, sea squirts, and birds. More specifically, the tissue of aquatic animals such as shellfish, sea squirts, sea cucumbers, salmon, pacific saury, and bonito is preferred as the animal tissue. Preferably, the animal tissue is shellfish tissue. Among the animal tissues, edible parts are preferred. The animal tissue may be cut tissue, or may be crushed tissue to more efficiently extract plasmalogen.

[0020] Examples of shellfish include bivalve or snail shells such as scallops, mussels, and abalone. As shellfish, scallops are particularly preferred. Scallops are edible bivalve shells belonging to the Pectinidae family, and examples thereof include scallops belonging to the Mizuhopecten or Pecten genus. Specific examples of shellfish include scallops (Mizuhopectenyessoensis) harvested in Japan and European scallops (Pectenmaximus (Linnaeus)) harvested in Europe. Examples of edible parts of scallops include the adductor muscle and string.

[0021] Sea squirts are edible chordates belonging to the family Halocynthidae, and examples of such sea squirts include those belonging to the genus Halocynthia or Halocynthia genus. Specific examples of sea squirts include Halocynthia roretzi and Halocynthia aurantium. The edible part of the sea squirt is the flesh (fascia).

[0022] The bird is, for example, an edible bird. Examples of the bird include chickens, silkie chickens, ducks, etc. As for the tissue of the bird, breast meat is preferable because it is rich in plasmalogens.

[0023] Plasmalogens can be extracted using an organic solvent or a water-containing organic solvent, preferably in combination with an enzyme treatment. Examples of methods for extracting plasmalogens include ethanol extraction and hexane extraction.

[0024] In the ethanol extraction method, the animal tissue may be exposed to an extracting solution containing ethanol. The extracting solution containing ethanol used in the extraction step may be aqueous ethanol or a mixture of ethanol and another organic solvent. The ethanol concentration in the extracting solution is 50% by mass or more, preferably 80% by mass or more, more preferably 95% by mass or more, and may be 100% by mass. The amount of ethanol used is, for example, preferably 100 to 3000 mL, more preferably 200 to 2000 mL, and even more preferably 250 to 1000 mL per 100 g of animal tissue. The extraction using ethanol may be performed multiple times.

[0025] Preferably, the animal tissue exposed to the extract containing ethanol is an animal tissue treated with a protease. The protease may be, for example, a protease derived from a filamentous fungus such as Aspergillus or Rhizopus; a protease derived from a bacterium such as Bacillus; or a protease extracted from a plant such as papaya or pineapple. A commercially available protease may be used as the protease. In particular, a protease derived from a filamentous fungus is preferred, and a protease derived from Aspergillus oryzae is more preferred. In addition, since plasmalogen is unstable in acidic and alkaline conditions, a neutral protease is preferred.

[0026] The amount of protease used is, for example, 0.1 to 10.0 g, preferably 0.2 to 8.0 g, and more preferably 0.3 to 5.0 g, per 100 g of animal tissue.

[0027] After the extraction, the solid content is removed to recover the extract, and if necessary, the extract is dried and solidified to obtain an extract containing plasmalogen. The extract may be subjected to a concentration treatment to concentrate the plasmalogen.

[0028] In the case of the hexane extraction method, the total lipids contained in the extract obtained by the ethanol extraction method are extracted with a mixed solvent of n-hexane and a water-soluble ketone solvent, and separated into an insoluble portion and a soluble portion. The water-soluble ketone solvent is, for example, acetone, methyl ethyl ketone, or a combination thereof, and is preferably acetone. When a mixture of n-hexane and acetone is used as the mixed solvent, the ratio is, for example, 4:6 to 6:4, preferably 4.5:5.5 to 5.5:4.5, in terms of volume ratio. The amount of the mixed solvent used is, for example, 10 to 30 mL per 1 g (dry mass) of total lipids.

[0029] The soluble portion obtained by the extraction process using the mixed solvent is dried and then extracted with a water-soluble ketone solvent, whereby the plasmalogen can be separated and recovered.

[0030] The content of plasmalogen in the adiponectin enhancer according to the present embodiment is appropriately adjusted. For example, the adiponectin enhancer contains 0.000001 to 99.9 mass%, 0.00001 to 99.8 mass%, 0.0001 to 99.7 mass%, 0.001 to 99.6 mass%, 0.01 to 99.5 mass%, 0.1 to 99 mass%, 0.5 to 60 mass%, 1 to 50 mass%, or 1 to 2 mass% of plasmalogen as an active ingredient.

[0031] The subject of administration of the adiponectin enhancer according to the present embodiment is a cell, a living tissue, an organism, an animal, etc. The adiponectin enhancer as a pharmaceutical is administered to humans and animals. The animals are preferably mammals, more specifically, dogs, cats, cows, pigs, horses, sheep, deer, etc.

[0032] The administration route of the adiponectin enhancer according to the present embodiment to humans is not particularly limited. The adiponectin enhancer is preferably used as an external preparation, an injection, or an oral preparation. The adiponectin enhancer may contain, for example, a plasmalogen and a pharmacologically acceptable carrier. The pharmacologically acceptable carrier is various organic carrier substances or inorganic carrier substances used as formulation materials. The pharmacologically acceptable carrier is, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent, etc. in a solid preparation, or a solvent, a dissolution aid, a suspending agent, an isotonicity agent, a buffer, a flavoring agent, etc. in a liquid preparation. In addition, additives such as a preservative, an antioxidant, a colorant, and a sweetener may be blended as necessary.

[0033] Examples of excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethylcellulose, gum arabic, pullulan, soft anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate, xylitol, sorbitol, and erythritol.

[0034] Examples of binders include, in addition to the above-mentioned excipients, pregelatinized starch, sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, and the like.

[0035] Examples of disintegrants include, in addition to the above-mentioned excipients, lactose, sucrose, starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethylstarch sodium, low-substituted hydroxypropylcellulose, soft anhydrous silicic acid, calcium carbonate, and the like.

[0036] Examples of lubricants include magnesium stearate, calcium stearate, talc, colloidal silica, polyethylene glycol, and the like.

[0037] Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben, alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol, benzalkonium chloride, acetic anhydride, sorbic acid, etc. Examples of the flavoring agent include sweeteners, acidulants, fragrances, etc.

[0038] Examples of the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil, etc. Examples of the solubilizing agent include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, tris(hydroxymethyl)aminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, etc.

[0039] Examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; polysorbates, and polyoxyethylene hydrogenated castor oil.

[0040] Examples of isotonicity agents include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, xylitol, fructose, etc. Examples of buffering agents include buffer solutions such as phosphates, acetates, carbonates, citrates, etc.

[0041] Examples of preservatives include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc. Examples of antioxidants include sulfites, ascorbates, etc. Examples of colorants include water-soluble colored tar dyes, lake dyes, natural dyes, etc. Examples of sweeteners include sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, etc.

[0042] The adiponectin enhancer according to this embodiment is produced by a known method and is provided in the form of, for example, a liquid, cream, ointment, tablet, granule, fine granule, powder, tablet, capsule, or the like.

[0043] The dosage of the adiponectin enhancer according to the present embodiment is appropriately determined depending on the age, weight, symptoms, etc., of the human or animal to which it is administered. The adiponectin enhancer is administered so that the plasmalogen is in an effective amount. An effective amount is the amount of plasmalogen necessary to obtain the desired result, that is, the amount necessary to delay, inhibit, prevent, reverse, or cure the progression of the condition being treated or treated.

[0044] The dosage of the adiponectin enhancer according to the present embodiment is, for example, 0.000001 μg or more per day for an adult, preferably 1 μg or more or 500 μg or more, more preferably 1000 μg or more. The upper limit is, for example, 20 mg per day, preferably 10 mg. The adiponectin enhancer can be administered once or multiple times per day. The adiponectin enhancer may also be administered at various administration frequencies, such as every other day, once a week, every other week, or once a month. It should be noted that amounts outside the above ranges may also be used as necessary.

[0045] Plasmalogen, which is the active ingredient in the adiponectin enhancer of this embodiment, has the effect of increasing the expression of adiponectin in intestinal cells and the amount of adiponectin in serum, as shown in the examples below.

[0046] The adiponectin enhancer according to this embodiment may be used as a reagent for the purpose of enhancing the expression of adiponectin in in vitro and in vivo experiments.

[0047] In another aspect of the present embodiment, there is provided an oral composition for enhancing adiponectin. Specific examples of the oral composition include supplements, food and drink compositions, functional foods, and food additives.

[0048] The form of the supplement is not particularly limited and may be any form such as tablets, powders, granules, capsules, sugar-coated tablets, films, lozenges, chewable tablets, solutions, emulsions, and suspensions. The supplement may contain any component normally used as a supplement.

[0049] The term "functional food" refers to food or beverage that is taken for the purpose of maintaining health, and includes foods with health claims, foods with functional claims, foods with nutrient functions, health foods, and nutritional supplements. As functional foods, foods with health claims or foods with nutrient functions are preferred. When commercializing functional foods, various additives used in foods, specifically colorants, preservatives, thickening stabilizers, antioxidants, bleaching agents, antibacterial and antifungal agents, acidulants, sweeteners, seasonings, emulsifiers, strengthening agents, manufacturing agents, and flavors, may be added to the oral composition for enhancing adiponectin.

[0050] The functional food may be either a food or a beverage, and is not particularly limited as long as it can be taken orally. Examples of functional foods include beverages, confectionery, processed grain products, paste products, dairy products, seasonings, and the like. Examples of beverages include nutritional drinks, soft drinks, black tea, green tea, and the like. Examples of confectionery include candy, cookies, tablet candy, chewing gum, jelly, and the like. Examples of processed grain products include bread, cooked rice, biscuits, and the like. Examples of paste products include sausages, ham, kamaboko, and the like. Examples of dairy products include butter, yogurt, and the like.

[0051] The adiponectin-enhancing oral composition may be added to food as a food additive. In this case, the food additive may be in the form of a paste, gel, powder, liquid, suspension, emulsion, granule, or the like so as to be easily added to food.

[0052] The oral composition for enhancing adiponectin according to the present embodiment may contain water, vitamins, minerals, organic acids, organic bases, fruit juice, flavors, functional ingredients, food additives, etc., within a range that maintains the effectiveness of enhancing adiponectin. The oral composition for enhancing adiponectin can be produced by a known method by adding ingredients other than plasmalogen as necessary.

[0053] The above-mentioned oral composition for enhancing adiponectin may be divided and stored in one or more containers so that the daily intake amount is the above-mentioned intake amount, in which case, preferably one container contains one day's worth of oral composition for enhancing adiponectin.

[0054] The above-mentioned oral composition for enhancing adiponectin is provided in an embodiment that can be distinguished from other products in that it contains plasmalogen and is used for enhancing adiponectin. For example, at least one of the packaging, instructions, and promotional materials of the product related to the oral composition for enhancing adiponectin indicates that it has an adiponectin enhancing function.

[0055] When the oral composition for enhancing adiponectin according to this embodiment is provided as a food or beverage composition, it may be provided or sold as a food or beverage labeled with the use of enhancing adiponectin (including health use). The act of "labeling" includes all acts for informing consumers of the above-mentioned uses. Any expression that can recall or infer the above-mentioned uses is considered an act of "labeling", regardless of the purpose of the labeling, the content of the labeling, the object or medium on which it is displayed, etc.

[0056] It is preferable that the "labeling" be done in an expression that allows consumers to directly recognize the above-mentioned uses. Specifically, this includes the acts of transferring, delivering, displaying for the purpose of transferring or delivering, or importing food and beverage products or product packaging on which the above-mentioned uses are written, displaying or distributing advertisements, price lists, or transaction documents related to the products and writing the above-mentioned uses in information containing the above-mentioned uses and providing them by electromagnetic means (such as the Internet), etc.

[0057] Examples of "labeling" include labeling as health food, functional food, enteral nutritional food, special purpose food, health functional food, food for specified health uses, nutrient functional food, functional food, medical drug, etc. Among these, in particular, labeling approved under systems related to foods for specified health uses, foods with nutrient functions, or foods with functional claims, or similar systems, etc. Specific examples include labeling as foods for specified health uses, labeling as foods for conditional specified health uses, labeling that indicates an effect on the structure or function of the body, labeling that reduces the risk of disease, labeling of functionality based on scientific evidence, etc. More specifically, typical examples include labeling as foods for specified health uses (especially labeling of health uses) and similar labeling.

[0058] In another aspect of this embodiment, there is provided use of plasmalogen for the manufacture of an adiponectin enhancer or an oral composition for enhancing adiponectin. In another aspect of this embodiment, there is provided a method for enhancing adiponectin, comprising administering plasmalogen to a subject. In another aspect of this embodiment, there is provided a plasmalogen for use in enhancing adiponectin. Note that adiponectin enhancement includes prevention, suppression, inhibition, and recovery of a decrease in adiponectin expression level.

[0059] The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples. EXAMPLES

[0060] [Preparation of sPls] Plasmalogen (sPls) was prepared from scallops (Mizuhopecten yessoensis) by the following method. sPls was extracted from raw scallops using hexane, as described in International Publication No. 2016 / 181491. In the extraction of plasmalogens from scallops, first, coclase P (manufactured by Mitsubishi Chemical Foods) and phospholipase A1 (PLA1, manufactured by Mitsubishi Chemical Foods) were added to the raw scallops and decomposed for 1 hour. Next, hexane / isopropanol was added and stirred, and after standing, the supernatant was suction filtered. An aqueous solution of sodium sulfate was added to the filtrate and mixed well, and the upper layer was dried and solidified using a rotary evaporator. 40 mL of acetone cooled to 4 ° C was added to this and mixed. Separation was performed using a centrifuge at 3000 rpm for 10 minutes at 4 ° C. The supernatant was discarded, the precipitate was collected, and dried overnight in a desiccator.

[0061] [Examination of adiponectin expression in rat intestinal cells] 12-week-old Wistar rats (n=5 per group) were administered sPls at a dose of 1 mg / kg in drinking water for 14 days (sPls group). After blood sampling and intracardiac perfusion with chilled phosphate-buffered saline (PBS), small intestinal tissues washed with chilled PBS were collected from the rats. Proteins were extracted from a portion of the small intestinal tissue for Western blotting. The remaining small intestinal tissues were subjected to immunohistochemical staining. Antibodies used for Western blotting or immunohistochemical staining were anti-adiponectin antibody (Cell Signaling Technology) and β-Actin (Santa Cruz). Cell nuclei were stained with DAPI.

[0062] Serum was separated from the blood, and adiponectin in the serum was quantified by ELISA (enzyme-linked immunosorbent assay) (Invitrogen, #A44838).

[0063] [result] Figure 1 shows the results of Western blotting compared to the control group that was not administered sPls. The relative change in adiponectin expression level based on the results of Western blotting was 2.84 times (standard deviation: 0.21, p<0.05).

[0064] Figure 2A shows a microscopic image of small intestinal tissue subjected to immunohistochemical staining. Ingestion of sPls increased the expression of adiponectin in intestinal epithelial cells. The arrows in Figure 2A indicate adiponectin-expressing cells. The relative number of adiponectin-expressing cells in Figure 2A is shown in Figure 2B. Ingestion of sPls significantly increased the number of intestinal epithelial cells expressing adiponectin.

[0065] Figure 3 shows the relative amount of adiponectin in serum as quantified by ELISA. Ingestion of sPls significantly increased adiponectin in serum.

[0066] [Examination of adiponectin expression in mouse intestinal cells] sPls was administered in drinking water to 8-week-old B6 male mice (C57BL / 6J) (5 mice per group, n=5) at a dose of 0.2 mg / kg per day for 14 days (sPls group). After intracardiac perfusion with chilled PBS, small intestinal tissue was collected from the mice. The small intestinal tissue was subjected to immunohistochemical staining using anti-adiponectin antibody (Cell Signaling Technology). Cell nuclei were stained with DAPI.

[0067] [result] Figure 4A shows microscopic images of small intestinal tissues subjected to immunohistochemical staining. Ingestion of sPls increased the expression of adiponectin compared to the control group not administered sPls. The relative number of adiponectin-expressing cells in Figure 4A is shown in Figure 4B. Ingestion of sPls significantly increased the number of intestinal epithelial cells expressing adiponectin. P values ​​were determined by Student's t-test.

[0068] [Examination of adiponectin expression by plasmalogen in mouse intestinal epithelial tissue culture] Small intestines were collected from 8-week-old adult male B6 mice (C57BL / 6J) after intracardiac perfusion with chilled PBS. A portion of the small intestinal tissue washed with chilled PBS was excised, digested with Accutase at 37°C, and dissolved in DMEM medium. The dissolved tissue was filtered through a 100 μm mesh. 50 μl of the obtained tissue fluid was mixed with 50 μl of Matrigel (BD Biosciences) and cultured in DMEM liquid medium containing 10% fetal bovine serum (FBS). After 48 hours of culture, sPls (5 μg / ml) was added to the medium and further cultured for 16 hours (sPls group). The cultured tissue was collected and RNA was extracted. Proteins in the medium supernatant were also extracted.

[0069] Quantitative reverse transcription PCR was performed on the extracted RNA to evaluate the expression level of AdipoQ. The expression level of AdipoQ was normalized with the endogenous control gene Gapdh. The nucleotide sequences of the forward primer and reverse primer for AdipoQ are shown in SEQ ID NOs: 1 and 2, respectively. The nucleotide sequences of the forward primer and reverse primer for Gapdh are shown in SEQ ID NOs: 3 and 4, respectively.

[0070] Adiponectin in the extracted proteins was quantified by ELISA (Invitrogen, #A44838).

[0071] [result] Figure 5 shows the relative expression level of AdipoQ compared to the control group not treated with sPls. The expression level of AdipoQ was significantly increased in primary culture of mouse intestinal tissue (n=8). Figure 6 shows the relative amount of adiponectin in the culture supernatant quantified by ELISA. Treatment with sPls significantly increased adiponectin in the culture supernatant (n=8).

[0072] The present invention allows various embodiments and modifications without departing from the broad spirit and scope of the present invention. The above-described embodiments are for the purpose of explaining the present invention and do not limit the scope of the present invention. That is, the scope of the present invention is indicated by the claims, not the embodiments. Various modifications made within the scope of the claims and the scope of the invention equivalent thereto are considered to be within the scope of the present invention. [Industrial Applicability]

[0073] The present invention is useful as an adiponectin enhancer.

Claims

1. Contains plasmalogen as an active ingredient. Adiponectin enhancer.

2. Contains plasmalogen as an active ingredient. An oral composition for enhancing adiponectin.

3. The plasmalogen is It is a plasmalogen extracted from animal tissue. The adiponectin enhancer according to claim 1 or the oral composition for enhancing adiponectin according to claim 2.

4. The animal tissue comprises: The tissue is an animal selected from the group consisting of shellfish, sea squirts, and birds. The adiponectin enhancer or oral composition for enhancing adiponectin according to claim 3 .

5. The animal tissue comprises: Scallop tissue, The adiponectin enhancer or oral composition for enhancing adiponectin according to claim 3 .

6. Use of plasmalogen for producing an adiponectin enhancer or an oral composition for enhancing adiponectin.

Images